|
|
|
51-200 employees
View all
|
|
biotechnology
|
|
72 Hammersmith Road,London,GB
|
|
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) andSLN124 to address beta-thalassaemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, pleasevisit: https://www.silence-therapeutics.com/
|
Silence Therapeutics plc Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}.{last} | [email protected] |
100%
|
The widely used Silence Therapeutics plc email format is {f}.{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Silence Therapeutics plc customer service number in your country click here to find.
Bill Abernethy is the CEO of Silence Therapeutics plc. To contact Bill Abernethy email at [email protected]. Or you may call 1 508 985 8715
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.